Royal Bank Of Canada Reaffirms “Sector perform” Rating for Smith & Nephew (LON:SN)

Smith & Nephew (LON:SNGet Free Report)‘s stock had its “sector perform” rating reiterated by stock analysts at Royal Bank Of Canada in a report issued on Monday,Digital Look reports. They currently have a GBX 1,350 price objective on the stock. Royal Bank Of Canada’s price objective suggests a potential upside of 18.58% from the company’s previous close.

SN has been the topic of a number of other reports. Berenberg Bank reaffirmed a “hold” rating and issued a GBX 13 target price on shares of Smith & Nephew in a report on Friday, May 1st. UBS Group reiterated a “neutral” rating and set a GBX 1,300 price target on shares of Smith & Nephew in a report on Tuesday, May 5th. Jefferies Financial Group restated a “buy” rating and issued a GBX 2,760 price objective on shares of Smith & Nephew in a research note on Thursday, May 21st. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a GBX 1,400 price objective on shares of Smith & Nephew in a research report on Thursday, June 11th. Three analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of GBX 1,382.62.

View Our Latest Stock Analysis on Smith & Nephew

Smith & Nephew Trading Down 0.7%

Shares of SN opened at GBX 1,138.50 on Monday. The company has a debt-to-equity ratio of 62.90, a quick ratio of 0.84 and a current ratio of 2.57. The stock’s fifty day moving average price is GBX 1,143.91 and its two-hundred day moving average price is GBX 1,211.61. The firm has a market capitalization of £12.48 billion, a P/E ratio of 40.99, a price-to-earnings-growth ratio of 0.46 and a beta of 0.67.

About Smith & Nephew

(Get Free Report)

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.

See Also

Analyst Recommendations for Smith & Nephew (LON:SN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.